SCHEMBL3512413

SCHEMBL3512413

c1ccc2oc(N3CCCCC3)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PRKDC P78527 9/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
KMT2A Q03164 1/20 0.49
ATM Q13315 3/20 0.49
MAPT P10636 2/20 0.49
POLB P06746 1/20 0.49
MAOA P21397 1/20 0.46
NPY5R Q15761 1/20 0.46
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
XRCC6 P12956 1/20 0.44
XRCC5 P13010 1/20 0.44
ACE P12821 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27581467 0.98 PRKDC (0.50) ALDH1A1HPGDL3MBTL1PRKDCNPC1
SCHEMBL6390592 0.84 CHRNB2 (0.48) ALDH1A1HPGDPRKDCNPC1RAB9A
SCHEMBL16470017 0.84 PRKDC (0.67) ALDH1A1PRKDCNPC1RAB9AKMT2A
SCHEMBL3237749 0.82 BCHE (0.49) ALDH1A1HPGDPRKDCATMMAOA
SCHEMBL20581416 0.82 PRKDC (0.52) ALDH1A1HPGDL3MBTL1PRKDCNPC1
SCHEMBL21047713 0.81 PRKDC (0.52) ALDH1A1HPGDL3MBTL1PRKDCNPC1
SCHEMBL3511781 0.80 PRKDC (0.44) ALDH1A1HPGDL3MBTL1PRKDCNPC1
SCHEMBL21047673 0.79 PRKDC (0.45) ALDH1A1HPGDL3MBTL1PRKDCNPC1
SCHEMBL28920975 0.77 NPC1 (0.55) ALDH1A1HPGDL3MBTL1NPC1RAB9A
SCHEMBL5867498 0.76 MAOA (0.56) ALDH1A1HPGDL3MBTL1PRKDCNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126840-A1 ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 EP disclosed
US-20100247543-A1 TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES ORYZON GENOMICS, S.A. (ES) 2010-09-30 US disclosed
EP-2195029-A2 TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES Oryzon Genomics SA (ES) 2010-06-16 EP disclosed
WO-2009027349-A2 TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES ORYZON GENOMICS SA (ES) 2009-03-05 WO disclosed
US-7378431-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-27 US disclosed
US-7375116-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-20 US disclosed
US-7365083-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-29 US disclosed
US-7361670-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-22 US disclosed
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-07-21 US disclosed
US-6919355-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2005-07-19 US disclosed
WO-2002034718-A1 AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2002-05-02 WO disclosed
EP-1122254-A2 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-08-08 EP disclosed
WO-2001009122-A2 SEROTONERGIC BENZOFURANS ELI LILLY AND COMPANY (US) 2001-02-08 WO disclosed
EP-0499586-B1 Substituted benzofuranyl-piperidine as nootropic CIBA GEIGY AG (CH) 1996-06-05 EP disclosed
US-5455254-A Administering to mammals to retard degenerative nerve disorders and improve cognition CIBA-GEIGY CORPORATION 1995-10-03 US disclosed
EP-0499586-A1 Substituted benzofuranyl-piperidine as nootropic CIBA-GEIGY AG (CH) 1992-08-19 EP disclosed
US-4600719-A Tetrahydropyridine and piperidine derivatives CIBA GEIGY CORPORATION (US) 1986-07-15 US disclosed
EP-0106800-A1 Furans CIBA-GEIGY AG (CH) 1984-04-25 EP disclosed
US-4210655-A Anti-depressant benzofuranyl piperidines CIBA-GEIGY CORPORATION (US) 1980-07-01 US disclosed
US-4210655-A Anti-depressant benzofuranyl piperidines CIBA-GEIGY CORPORATION (US) 1980-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B ALDH1A1 3627/4885HPGD 1635/4885L3MBTL1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.